Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.02 USD
Change Today +0.30 / 3.44%
Volume 2.0M
ZIOP On Other Exchanges
As of 4:30 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Caesar J. Belbel

Chief Operating Officer, Chief Legal Officer, Executive Vice President and Secretary,ZIOPHARM Oncology, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

As of Fiscal Year 2014


Mr. Caesar J. Belbel has been the Chief Operating Officer at ZIOPHARM Oncology, Inc. since June 2015. Mr. Belbel has been the Chief Legal Officer, Executive Vice President and Secretary at ZIOPHARM Oncology, Inc. since September 6, 2011 and is responsible for ZIOPHARM's legal affairs. Mr. Belbel serves as the Chief Legal Officer and Executive Vice President at Trovis Pharmaceuticals LLC. He served as Chief Legal Officer, Executive Vice President and Secretary at Avalon ...

Read Full Background

Corporate Headquarters*

Parris Building 34
Boston, Massachusetts 02129

United States

Phone: 617-259-1970
Fax: 617-241-2855

Board Members Memberships*

There is no Board Members Memberships data available.


Columbia University
Boston College Law School

Other Affiliations*

Annual Compensation*

Total Annual Compensation$472,500

Stock Options*

All Other Compensation$2,342
Exercisable Options476,667
Exercisable Options Value$376,368
Unexercisable Options428,333
Unexercisable Options Value$506,732
Total Value of Options$883,100
Total Number of Options905,000

Total Compensation*

Total Annual Cash Compensation$474,842
Total Short Term Compensation$472,500
Other Long Term Compensation$2,342
Total Calculated Compensation$1,112,962
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $9.02 USD +0.30


Ali Fattaey Ph.D.Chief Executive Officer, President and Director
Curis, Inc.
Jeffrey D. Abbey MBA, J.D.Chief Executive Officer, President and Director
Argos Therapeutics, Inc.
Eddie Gray Chief Executive Officer and Director
Dynavax Technologies Corporation
Daniel J. O'Connor Esq.Chief Executive Officer, President and Director
Advaxis, Inc.
William D. Clark Chief Executive Officer, President and Director
Genocea Biosciences, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at